Oxomemazine is an antihistamine and anticholinergic of the phenothiazine chemical class for the treatment of cough. It is an H1 receptor antagonist with central nervous system penetration that provides suppression of cough reflex sensitivity in addition to traditional antihistaminic activity; antimuscarinic properties contribute to drying of bronchial secretions and mild sedative effects. Chemically it is a substituted phenothiazine derivative typically formulated for oral administration as syrups or tablets. The substance is primarily metabolized by hepatic oxidative pathways to polar metabolites and eliminated by renal excretion. Typical pharmaceutical presentations are designed for symptomatic relief of cough associated with upper airway irritation and for short term symptomatic control of allergic rhinorrhea, with dosing regimens set to balance efficacy and sedative potential.
Parent: Oxomemazine
Parent: Trimeprazine / Oxomemazine
Related compounds and typical impurities for oxomemazine include oxidative and N-dealkylation products such as N-desmethyl derivatives, N-oxide species, sulfur-oxidized forms (sulfoxides), and low-level ring-oxidation/degradation products formed on storage or during synthesis. Typical quality specifications used by manufacturers and regulatory guidance commonly control individual known related compounds at low single-digit parts-per-hundred levels; for example known related impurities are frequently limited to 0.1 to 0.5 percent by weight each and total impurities are commonly limited to 1.0 to 2.0 percent, with tighter limits applied for genotoxic or unspecified impurities in accordance with ICH Q3A/B thresholds. Residual solvents, heavy metals and particulate matter are controlled separately to pharmacopeial limits, and stability testing monitors increases in specific degradation products over shelf life.
Oxomemazine is used primarily as a symptomatic treatment for cough related to upper airway irritation and as an antihistamine for relief of allergic nasal symptoms; its anticholinergic activity also reduces secretions and it may produce mild sedation which can contribute to symptomatic relief.
No. Oxomemazine is not a steroid. It is a phenothiazine-class antihistamine with anticholinergic properties.
Safety data in pregnancy are limited. Because oxomemazine has central nervous system and anticholinergic effects and crosses the placenta, it is generally avoided in pregnancy unless a healthcare professional determines the potential benefit justifies potential risk. Patients should consult their prescriber for individual assessment.
Oxomemazine is marketed under various brand names and as generic products depending on the country. One commonly referenced brand name in some markets is Toplexil; other local brand names and generic formulations may be available.
